Hologic touts growing 3D breast imaging sales, updates on $3.7B Gen-Probe merger | Wall Street Beat
Women's health devices maker Hologic gets some Wall Street love after releasing financials touting a significant shift from its 2D breast imaging devices to the next-gen 3D systems.
Massachusetts-based women's health devices maker Hologic (NSDQ:HOLX) got some attention on Wall Street after releasing a preliminary earnings report predicting that it would meet or exceed expectations for the 3rd quarter.
Hologic announced that it expects to beat its 34¢ guidance as sales of its Dimensions 3D breast tomosynthesis systems are ramping up more quickly than anticipated.
The device maker has already attained more 45% of its 2-year goal of installing between 500 and 700 of the new 3D systems in the U.S., and expects to reach 60% of the goal by the end of the year.